Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

NCT01992549 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Octapharma